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Abstract 
 
PCOS is the most common reason to anovulatory infertility, and previous observations 
suggest that the fertility in these women increases when ageing. We wanted to 
investigate whether PCOS women have an increased age related ovarian response to 
ovulation induction, compared to patients with normal ovaries, with respect to the 
number of collected oocytes, clinical pregnancies and live births.  
1500 patients ranging from 20-44 years of age were evaluated in this study. 
By selection of patients from our clinical database at Kvinneklinikken, Rikshospitalet, 
we ended up with a case cohort of 500 infertile women with PCOS treated with IVF. 
Two control cohorts were selected from infertile women with tubal factor infertility 
only and male factor infertility only. A similar distribution of age among the groups 
was obtained by matching, ending with 500 patients in each group.  
In the PCOS group, no significant association between age and number of collected 
oocytes was observed. In the tubal and male factor infertility groups, advanced age was 
associated with reduced number of retrieved oocytes. In the PCOS and the male factor 
infertility groups, a significant association between age and live birth rate were not 
observed. In the tubal factor infertility group, advanced age was associated with a 
significantly reduced probability for live birth. 
The results demonstrate that the ovarian capacity to release oocytes remain stable with 
advancing age in PCOS women, whereas it decreases in control women. It may also 
indicate that PCOS women do not have a decline in fertility until at least 40 years of 
age, whereas it decreases in normal controls.  
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Introduction 
 
The polycystic ovary syndrome is the most common endocrine and metabolic 
abnormality affecting 6-8% of women in their reproductive age1 and the most common 
reason to anovulatory infertility2. It is characterized by anovulation, hyperandrogenism 
and polycystic ovaries (PCO) on ultrasonography. The menstrual irregularities in PCOS 
women are characterized by oligo- or amenorrhea with infrequent or absent ovulation 
leading to infertility. These women often have a normal or slightly delayed onset of 
menarche. In some women the menstrual irregularities do not start before they gain 
weight. The clinical signs of hyperandrogenism are hirsutism with thick and pigmented 
facial and/or body hair in a typically male pattern, acne and in some cases male pattern 
hair-loss. 
In addition, some PCOS women have dyslipidemia3, 9-17% the metabolic syndrome4, 
50-70% insulin resistance5 and thus an increased risk of developing type 2 diabetes 
mellitus6, and possibly cardiovascular diseases7.  
 
The mechanisms responsible for the elevated androgen levels is thought to be caused 
by an increased production and secretion of androgens by hyperplastic theca cells8. A 
possible increase in pulsatile release of gonadotrophin releasing hormone (GnRH) from 
the hypothalamus leads to an increased release of luteinising hormone (LH) from the 
pituitary gland. The cause of the syndrome remains uncertain, but it is most likely 
linked to genetic factors9  with abnormal follicle growth and maturation10.  
 
Generally, fewer follicles grow per cycle and pregnancy rates decline with advancing 
age11, 12 as oocyte quantity and quality will rapidly decline in the late thirties13. Thus, 
about 1/3 of women at 35 and ½ of normal women at 41 years of age are infertile14.  
PCOS patients have an enlarged follicle cohort15, and have significantly more oocytes 
collected in in vitro maturation programs compared to normal controls16. However, on 
ultrasound examination of the ovaries, Bili et al found that older PCOS women present 
a reduced number of ovarian follicles in response to gonadotropin stimulation 
compared to younger PCOS women17.  
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PCOS women are born with an increased population of germ cells or have a decreased 
rate of oocyte loss until puberty15. 
Thus, the aim of this study was to investigate whether PCOS women have an increased 
age related ovarian response to ovulation induction, compared to patients with normal 
ovaries, with respect to the number of collected oocytes, clinical pregnancies and live 
births.  
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Methods 
In this section, I will make a brief summary of the most important conciderations that 
were made in our study, based on the work of Peter Fedorcsák and Jan Mellembakken.  
Selection of patients 
All patients used for this case-control study were retrospectively identified from a 
clinical database at the Department of Obstetrics and Gynecology, Rikshospitalet. 
Approval from database query was obtained from the “Ombudsmann for Privacy and 
Data Protection”.  
 
The PCOS group consisted of patients with at least two of the following three 
conditions present: oligomenorrhea or amenorrhea, hyperandrogenism or hirsutism and 
polycystic ovaries (Rotterdam criteria, 200318).  Patients with NCAH (non-classical 
congenital adrenal hyperplasia), Cushing’s syndrome, androgensecreting tumours and 
hyperprolactinemia were excluded by appropriate tests. Patients with co-existing 
diseases, including tubal disease, male factor infertility and endometriosis were 
excluded by a thorough review of clinical records. In the end our case cohort contained 
500 PCOS women from 20-44 years of age.  
We decided to have two control groups. 500 women who were treated with IVF or ICSI 
for tubal factor infertility and 500 women with male factor infertility were selected by 
matching each woman in the PCOS group to the control groups by age. Women with 
other co-existing  conditions, including endometriosis, PCOS, as well as history of 
ovarian surgery were excluded from the control groups.   
Ovarian stimulation and fertilization in vitro  
 
In vitro fertilization (IVF) is a procedure where the ovaries are stimulated and oocytes 
are collected from the ovarian follicles to be fertilized in vitro and eventually one or 
two embryos are being transferred back to the uterus. 
Before this IVF cycle, both partners should have a complete infertility evaluation.  
In PCOS women, IVF is performed when other treatments like weight loss and 
ovulation induction with clomiphene citrate show no effect on fertility. 
Intracytoplasmatic sperminjection (ICSI) is a technique in which a single sperm is 
injected directly into the cytoplasm of a mature oocyte to treat male factor infertility. 
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In some cases, the use of gonadotrophins for ovulation induction may cause 
complications. One concern is the increased incidence of multiple pregnancies with an 
increased risk of perinatal mortality and morbidity. Another is the ovarian 
hyperstimulation syndrome (OHSS), that may occur during excessive ovarian 
stimulation and is a potentially life-threatening complication to ovulation induction. 
 
All patients had an ultrasound examination of the ovaries before being treated with 
IVF. The age, weight and presence of PCO or not, decided the FSH dose given to the 
patient. 
Pituitary down regulation was achieved with GnRH agonist administered intranasally 
from the mid-luteal phase of the preceding cycle. Recombinant FSH or human 
menopausal gonadotrophin was given for ovarian stimulation. The standard starting 
dose was 75 IU daily in the PCOS group and 150 IU daily in the control groups. 
Women older than 35 received 200-225 IU daily FSH as starting dose. The dose was 
adjusted after 4-9 days according to the ovarian response19.  
Collected oocytes were fertilized with ejaculated apermatozoa in vitro by IVF or ICSI, 
using standard procedures19. In order to reduce the effect of dose adjustment based on 
prior treatment experiment, only the first treatment of patients with multiple treatment 
cycles was considered. Pregnancies was defined by serum hCG concentration > 20 IU/l 
on day 16 after embryo transfer. 
OHSS was diagnosed by combination of clinical symptoms as abdominal distension, 
nausea, excessive follicle development or ascites. Body mass index (BMI, kg/m2) was 
assessed at the first visit using the same weight scale and height stock.  
 
 
 
Data analysis 
Data are shown as mean and standard deviation or median and range. Findings was 
considered statistically significant at P<0.05. 
The association between the number of collected oocytes and age was assessed by 
using multiple regression analysis, after controlling for mean daily FSH dose and BMI. 
T-test was used to find the regression coefficients (slopes) for age comparing the 
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groups. To find any association between birth rate and age, logistic regression analysis 
was used after controlling for the number of collected oocytes.  
  
 
Literature 
 
The search for literature has been directed to find related articles for the study and to 
find articles and reviews to learn more about the subject of PCOS, by using 
MedLine/Pubmed. My mentor also provided some articles relating to our study. 
Searchword like PCOS and age/ageing/IVF/oocytes/fertility/infertility was used to 
narrow the searchfield. In some cases articles was found by using the references in 
other articles to search by names, title and in some cases year/date of publishing. 
UpToDate.com and teaching textbooks in gynecology provided much background 
information on PCOS. Topics here were clinical manifestation, epidemiology, 
pathology, diagnosis and treatment.  
 
 
 
How I assessed the articles found in the search 
• Is it clear in the introduction which population is being studied and the 
intervention given? 
• Is the study randomised and is it the best way of answering the question? Is it a 
good enough randomisation procedure (blinded etc)? 
• If two groups are compared, are they comparable? Are the groups equal 
enough? (Selection bias? –confounding variables? Observation bias? ) 
• Did the groups get the same treatment? 
• Is there a statistical significant difference between the groups? 
• Could the results just be a coincidence? –what is the confidens interval and p-
value? 
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Results 
 
 PCOS 
(n=500) 
Tubal factor 
(n=500) 
Male infertility 
(n=500) 
P-value 
Age (years) 31.3 (3.6) 31.6 (3.2) 31.3 (3.3)  
BMI (kg/m2) 26.5 (5.2) 23.5 (3.9) 23.9 (4.0) <0.001 
Total FSH-dose  
(IU, median 
range) 
1650 (525-9825) 1725 (525-2500) 1650 (450-11675) 0.08 
Duration of FSH 
treatment (days) 
12 (6-39) 11 (6-28) 10 (5-19) <0.001 
No. of oocytes 
collected 
9 (0-39) 9 (0-33) 10 (0-41) 0.19 
No. of diploid 
fertilized oocytes 
5 (0-25) 6 (0-23) 4 (0-20) <0.001 
No. of transferred 
embryos 
2 (0-3) 2 (0-3) 2 (0-3)  
Pregnancy rate 
(hcg +)  
169 (33.8%) 169 (33.8%) 168 (33.6%) 0.99 
Pregnancy loss  47 (27.8%) 36(21.3%) 37 (21.4%) 0.28 
No. of live births 121 (24.2%?) 124 (24.8%?) 125 (25.0%?) 0.954 
Ovarian 
hyperstimulation 
syndrome 
11 (2.2%) 3 (0.6%) 1 (0.2%) 0.004 
 
Table 1 
Clinical characteristics, ovarian stimulation and treatment outcome among age matched 
women with PCOS, tubal factor infertility and male factor infertility undergoing 
assisted reproduction treatment. 
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The mean body mass index (BMI) was, as expected, significantly higher in the PCOS 
group than the control groups (P<0.001, Table 1). Statistically there was no difference 
among the groups in the number of oocytes collected. But when using multiple 
regression analyses with age, mean daily FSH doses and BMI as variables it shows that 
in the PCOS group there is no association between age and the number of collected 
oocytes. In both the tubal factor infertility group and male factor infertility group 
advanced age was associated with a reduced number of retrieved oocytes (Figure 1). 
The duration of FSH treatment is significantly longer for PCOS women, but the total 
FSH dose given is the same between the groups. The number of fertilized oocytes is 
higher (p<0.001) in the tubal factor group compared to the PCOS group, but not 
compared to the male factor infertility group. There was no statistical difference in 
pregnancy rate and pregnancy outcome between the groups, but age-related changes are 
shown when using logistic regression analysis. In the tubal factor infertility group, 
advanced age was associated with a significantly reduced probability for live birth. This 
was not shown in the PCOS and male factor infertility group (Figure 2). The prevalence 
of ovarian hyperstimulation syndrome (OHSS) was as expected higher in the PCOS 
group compared to the control groups (Table 1).  
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Figure 1. 
Age-related changes in the number of oocytes collected after ovarian stimulation with 
FSH in age-matched women treated for PCOS, tubal factor infertility and male factor 
infertility. The observed data were plotted using smoothed color density representation 
for the number of observations. Fitted solid lines indicate the association between age 
and the number of collected oocytes, and were derived from multiple regression 
analysis using age, mean daily FSH dose, and BMI as covariates. 
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Figure 2. 
Age-related changes in live birth rate after assisted reproduction treatment among age-
matched women treated for PCOS, tubal factor infertility and male factor infertility. 
Bars indicate observed live birth rate in the given age categories with the number of 
live births enclosed in the bars. Fitted lines indicate the association between age and 
live birth rate, and were derived from logistic regression analysis using age and the 
number of collected oocytes as covariates.  
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Discussion 
 
The results in our study shows that PCOS women’s capacity to release oocytes during 
IVF treatment does not decline and remains stable with increasing age up to <45 years, 
whereas it decreases in the control groups. In addition, we found no association 
between age and live birth rate in PCOS women.  
In the tubal factor infertility group the fertility decreased whereas in the male factor 
group the decrease with age was not significant. However, it is possible this would 
have reached a statistically significant level with a larger control group. 
  
Our results are in contrast to Guido et al who found an age related decline in the 
response to a low-dose gonadotrophin ovulation induction treatment in PCOS 
patients20. One reason for the difference in findings may be that Guido et al did use a 
low-dose regime, in order to induce unifollicular ovulation in PCOS patients. In in vitro 
maturation programs, where patients are not given FSH stimulation, PCOS patients 
have an increased number of oocytes collected compared to controls21. 
 
The duration of FSH treatment is in our study significantly longer for PCOS women, 
but the total FSH dose given is the same between the groups. Because of the risk of 
OHSS, ovarian hyperstimulation syndrome, PCOS women receive a lower starting 
dose, in order to prevent this complication. The starting dose of FSH is about half the 
dose of other IVF-treated women19. It has been presumed, that PCOS women need a 
smaller dose of FSH for oocyte maturation, but the results of this study indicate that 
they may need the same amount of FSH as normal controls to achieve oocyte 
maturation for IVF.  
 
Ovarian ageing is an irreversible process. The number of follicles declines with age, 
faster after the age of 37.5, leading to the menopause at around 51 years of age22, 23. 
Secondary to the physiological ovarian failure, FSH begin to increase in the early 
follicular phase at the age of 3524. The LH secretion changes around the age of 4523. 
In normo-ovulatory women, the Anti-Müllerian hormone(AMH) levels decline with 
age25. These levels are correlated to the number of antral follicles with AMH having the 
best correlation26. 
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Polycystic ovaries in young women have twice the number of primary follicles 
compared to normal age-matched ovaries17, 27-29 and up to a sixfold increase in the 
number of primordial and primary follicles in anovulatory women with PCOS 
compared to normal regularly cycling women15.  A high number of follicles producing 
an increased level of androgens contributing to menstrual irregularities and anovulation 
clinically and possibly contribute to the lower number of oocytes recruited from PCOS 
women before 28 years of age, compared to controls (figure 1). However, it may also 
reflect that PCOS women may have a slower growth through pre-antral stages 
compared to controls15. 
 
The influence of age on fertility of PCOS women, have seldom been discussed in the 
literature, but has been presumed to impair treatment outcome30. A decrease in the 
follicular pool is also present in ageing PCOS women17. But the decrease in inhibin B, 
that follows the follicular loss24, 31, may facilitate more regular and more frequent 
ovulatory cycles in these women. Because anovulatory PCOS women have a larger 
follicular pool, they are unlikely to undergo a rapid depletion of their ovarian reserve13. 
This is supported by that the decrease in AMH when ageing is less obvious in PCOS 
women, possibly contributing to a longer reproductive life compared to controls21. 
PCOS ovaries may contain both an increased number of oocytes and release them 
slower, ending up with an increased number of oocytes and sustained fertility later in 
life. This is supported by the clinical observation by Vulpoi et al. that spontaneous 
pregnancies did occur late in life in three previously infertile PCOS women32. Because 
these women became pregnant years after their last infertility treatment, no hormonal 
tests and clinical evaluations were done prior to the spontaneous pregnancies, and it 
should have been a larger study investigating PCOS women over time to see if this 
increase in fertility is significant. 
 
In conclusion, as PCOS women may possess a higher number of oocytes throughout 
fertile years and obtain a more favourable inhibin B level late in life, they may have an 
increased release of oocytes and unchanged fertility with advancing age compared to 
controls. Regarding the fertility, our study conclude that PCOS women does not have a 
decline in fertility with increasing age up to 40 years of age. 
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